for hers compounded semaglutide Hims & stock falls 25% as FDA curtails GLP-1s VIEW Hims and Hers Health's

Ozempic Lawsuit FAQ 1

Because glucagon receptor activation directly drives hepatic fat oxidation, compounds with the glucagon component survodutide and retatrutide show stronger liver fat reduction data than tirzepatide

From their beginnings as a treatment for type 2 diabetes, GLP-1 receptor agonists such as the semaglutide drugs Ozempic and Wegovy and the tirzepatide drugs Mounjaro and Zepbound have seen an explosion in use, most popularly for weight loss

All products are sold strictly for laboratory research use and are not intended for human consumption, injection, or therapeutic use

Phase 3 clinical trials are ongoing, and regulatory submissions to bodies such as the US Food and Drug Administration (FDA) and potentially the EMA and MHRA may follow in due course, depending on trial outcomes

however approval is not guaranteed and first-movers face high risk USA/Australia & New Zealand/India There may be limited scope to reference GLP-1 through self-substantiated claims, but this carries increased compliance risk For global brands, aligning product positioning, claims and labelling strategies across these differing frameworks will be a key challenge